Posts by: Patricia Silva, PhD

Esbriet, News

Spherix Global Insights, GmbH, a business intelligence and market research company based on Switzerland, recently reported a study revealing that idiopathic pulmonary fibrosis (IPF) remains a challenge in terms ... Read more

December 30, 2015July 26, 2016

Systemic Sclerosis Patients with ILD Being Asked to Participate in Phase 3 Study of OFEV

News

Boehringer Ingelheim recently announced the enrollment of the first patient in its Phase 3 clinical trial, called SENSCIS (Safety and Efficacy of Nintedanib in Systemic Sclerosis), evaluating the safety and ... Read more

December 28, 2015December 28, 2015

Potential Therapy for IPF and Fatty Liver Disorders Shows Safety in Early Clinical Trial

News

DS Biopharma, headquartered in Dublin, Ireland, and focused on therapies for inflammatory and fibrotic skin and pulmonary disorders, recently announced that a Phase 1 clinical trial evaluating safety and dosing ... Read more

December 17, 2015December 17, 2015

UC Medical Center Joins Pulmonary Fibrosis Foundation’s Care Center Network

News

The University of Cincinnati (UC) Medical Center is among the 19 medical centers recently invited after careful review to become part of the Pulmonary Fibrosis Foundation (PFF) Care Center Network. ... Read more

December 9, 2015December 9, 2015

UVA Joins Pulmonary Fibrosis Foundation’s Care Center Network

News

The University of Virginia Health System (UVA) recently joined the Pulmonary Fibrosis Foundation (PFF)’s Care Center Network, making it one of 19 new facilities chosen after careful peer review for inclusion in ... Read more

December 4, 2015December 4, 2015

‘Organs on Chips’ May Revolutionize Lung, Other Disease Research

News

Researchers at the University of Miami (UM), led by Assistant Professor Ashutosh Agarwal, are developing functional organs able to mimic real human organs. These laboratory-developed structures, based on chips, could ... Read more

November 30, 2015November 30, 2015

IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial

News

Afferent Pharmaceuticals, a biotechnology company dedicated to therapies for neurogenic disorders, recently announced the beginning of a Phase 2 clinical trial to assess its candidate product AF-219 for the ... Read more

November 25, 2015April 12, 2017

Genentech’s IPF Therapy Found to Improve Lung Function over Time

Esbriet, News

New data from Phase 3 clinical studies of Genentech’s Esbriet (pirfenidone), a drug developed for the treatment of pulmonary fibrosis (PF), showed the treatment’s efficacy over time. The data ... Read more

November 20, 2015November 20, 2015

New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial

News

miRagen Therapeutics, Inc., a biopharmaceutical company dedicated to the development of pioneering therapies based on microRNAs, recently announced the start of a Phase 1 clinical trial on the company’s ... Read more

Posts by: Patricia Silva, PhD

Patricia Silva, PhD

IPF Patients and Doctors on Lookout for New Treatment Approaches

Systemic Sclerosis Patients with ILD Being Asked to Participate in Phase 3 Study of OFEV

Top 10 Pulmonary Fibrosis Articles of 2015

Potential Therapy for IPF and Fatty Liver Disorders Shows Safety in Early Clinical Trial

UC Medical Center Joins Pulmonary Fibrosis Foundation’s Care Center Network

UVA Joins Pulmonary Fibrosis Foundation’s Care Center Network

‘Organs on Chips’ May Revolutionize Lung, Other Disease Research

IPF Patients with Chronic Cough Sought for Phase 2 Clinical Trial

Genentech’s IPF Therapy Found to Improve Lung Function over Time

New Anti-Fibrotic Drug Candidate MRG-201 Enters Phase 1 Clinical Trial

Pin It on Pinterest